Amgen: Myelodysplastic Syndromes trials

The registry lists 11 Myelodysplastic Syndromes studies with Amgen as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 5Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic LeukemiaTerminatedNCT05209152Phase 1Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesTerminatedNCT03465540Phase 1Results posted
• A Phase 1 Study of AMG 330 in Subjects With Myeloid MalignanciesTerminatedNCT02520427Phase 1Results posted
• Darbepoetin Alfa MDS Companion ProtocolCompletedNCT02175277Phase 3Results posted
• Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01362140Phase 3Results posted
• Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT00614523Phase 2Results posted
• Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)CompletedNCT00472290Not applicableResults posted
• A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidCompletedNCT00418665Phase 2Results posted
• Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsCompletedNCT00321711Phase 2Results posted
• Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT00303472Phase 2Results posted
• A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic SyndromeCompletedNCT00095264Phase 2